Overview
- The Danish Patient Compensation association has decided five of 43 claims tied to the drugs, awarding four patients and dismissing one.
- Combined compensation totals 800,000 Danish crowns, funded by the state, with amounts subject to change based on long‑term impact.
- EU regulators in June classified non‑arteritic anterior ischemic optic neuropathy as a very rare adverse reaction to semaglutide, up to 1 in 10,000 users.
- Novo Nordisk updated product information and patient leaflets to include the risk and maintains the overall benefit–risk profile remains favorable.
- The association described the cases as very complex and required input from an optic‑nerve specialist to assess causality.